3rd Quarter - Report

ARTEMIS POLICY GROUP LLC for THE HEMOPHILIA ALLIANCE

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Issues related to reimbursement for hemophilia services and treatments in Medicare: comments on proposed HOPPS rule (CMS-1850-P) Issues related to reimbursement for hemophilia services and treatments in Medicaid Implementation of H.R. 1, One Big Beautiful Bill Act Implementation of Medicaid Community Engagement requirements: comments on Medicaid community engagement IFR (CMS-2454-IFC)

LobbyistCovered position, as disclosed
MIRIAM GOLDSTEIN New —
JOHANNA GRAY Intern, Senator Barack Obama
ELIZABETH JULIA KARAN New —
ELLEN RIKER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1 (119th)

Insurance INS

Implementation of H.R. 1, One Big Beautiful Bill Act Affordable Care Act implementation Coverage of hemophilia treatments and services in private insurance plans: comments on essential health benefits review, RIN 0938-AW02 Policies related to co-pay accumulators and maximizers, including the HELP Copays Act (S 864, HR 6423) Policies related to the operations of pharmacy benefits managers Private insurance policies that discriminate coverage for high-cost drugs and use of patient assistance programs, also known as Alternative Funding Programs

LobbyistCovered position, as disclosed
MIRIAM GOLDSTEIN New —
JOHANNA GRAY Intern, Senator Barack Obama
ELIZABETH JULIA KARAN New —
ELLEN RIKER —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: H.R. 1 (119th), H.R. 6423 (119th)

Pharmacy PHA

Issues related to participation in the 340B Drug Discount Program Polices related to PBMs and drug cost transparency 340B Drug Pricing Integrity and Affordability for Patients Act discussion draft SECURE 340B Act, HR 9599 SUSTAIN 340B Act, S. 5244 Comments on Senate Finance Committee RFI on drug pricing

LobbyistCovered position, as disclosed
MIRIAM GOLDSTEIN New —
JOHANNA GRAY Intern, Senator Barack Obama
ELIZABETH JULIA KARAN New —
ELLEN RIKER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 5244 (119th), H.R. 9599 (119th)

Budget/Appropriations BUD

Funding for federal hemophilia programs at CDC and HRSA for FY27 Funding and staffing for the CDC Division of Blood Disorders and Public Health Genomics: Letter to CDC Director Erica Schwartz re Division of Blood Disorders & Public Health Genomics

LobbyistCovered position, as disclosed
MIRIAM GOLDSTEIN —
JOHANNA GRAY Intern, Senator Barack Obama
ELIZABETH JULIA KARAN —
ELLEN RIKER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.